The combination of G-CSF and AMD3100 mobilizes bone marrow-derived stem cells to protect against cisplatin-induced acute kidney injury in mice

Abstract Background Several studies have confirmed that mobilizing bone marrow-derived stem cells (BMSCs) ameliorates renal function loss following cisplatin-induced acute kidney injury (AKI). The aim of this study was to explore whether the combination granulocyte-colony stimulating factor (G-CSF) and plerixafor (AMD3100) exerts beneficial effects on recovery in a model nephrotoxicity. Methods C57BL/6J mice received intraperitoneal injections G-CSF (200 μg/kg/day) for 5 consecutive days. On day last injection, single subcutaneous dose AMD3100 (5 mg/kg) 1 h before cisplatin 20 mg/kg injection. Ninety-six hours after were euthanized, blood tissue samples collected assess damage. Cell mobilization assessed by flow cytometry (FCM). Results Mice pretreated with G-CSF/AMD3100 exhibited longer survival lower serum creatinine urea nitrogen (BUN) levels than treated only or saline. Combinatorial treatment attenuated cell death, enhanced regeneration, mobilized higher number peripheral saline treatment. Furthermore, mRNA expression proinflammatory factors lower, whereas anti-inflammatory higher, group (all P < 0.05). Conclusions These results suggest combinatorial therapy mobilizes BMSCs accelerate improvements functions prevent tubular injury. This may represent new therapeutic option AKI should be further investigated future.